News by community
05.09.2019 Abionic Signs Agreement to Optimize Asthma Management in the U.S. through Innovative Rapid Point-of-Care Tests
Biopôle, Lausanne, Switzerland, 5th September 2019 – Abionic SA, the developer of proprietary disruptive nanotechnology based rapid diagnostic solutions, and Genentech, a
member of the Roche Group, announced today a strategic agreement to develop and provide an In Vitro Diagnostic (IVD) Asthma Test Panel using Abionic’s POC abioSCOPE®
platform in the United States. Abionic’s POC abioSCOPE®, a compact, ultra-fast medical device powered by a patented nanofluidic technology, determines blood levels of
immunoglobulin E (IgE), an underlying cause of allergic asthma. The platform provides labquality results in five minutes from a single drop of blood at the POC, enabling rapid
diagnosis and the possibility of immediate treatment initiation.
Under the terms of the agreement, Abionic will carry out all pre-market process requirements for a specific Asthma Test Panel to quantify total IgE as well as IgE levels to 5 major
perennial allergens associated with allergic asthma. Genentech will fund all clinical and regulatory costs for the tests.